Vivani Medical subsidiary Cortigent files for IPO; Vivani to fund ops until offering

Vivani Medical, Inc.

Cortigent, Vivani's neuromodulation subsidiary, filed S-1 for IPO; ThinkEquity sole book-runner.
Vivani agrees to fund Cortigent salaries, rent, overhead until Dec 31, 2024 or IPO close.
Cortigent must repay all advanced funds plus accrued interest after funding support term.
Cortigent will be controlled by Vivani post-IPO, led by CEO Jonathan Adams.
IPO subject to market conditions; no assurance of completion or terms.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vivani Medical, Inc. entered into Transition Funding, Support and Services Agreement with Cortigent, Inc. (effective 2023-03-19).

Action: entry
Counterparty: Cortigent, Inc.
Effective: 2023-03-19

Exact text from the filing

On March 19, 2023, the Company and Cortigent, Inc. (“Cortigent”), a wholly owned subsidiary of the Company entered into a Transition Funding, Support and Services Agreement (the “TFSSA”), pursuant to which the Company has agreed to advance funds and provide or cause to be provided to Cortigent the services and funding intended to cover salaries and related costs, rent and other overhead in order to permit Cortigent to operate in substantially the same manner in which business operations of Cortigent were previously operated by Second Sight Medical Products, Inc., prior to the formation of Cortigent, which obligations will continue, in the case of the funding obligations, until the earlier of December 31, 2024 or the closing of an initial public offering of Cortigent (the "Funding Support Term").

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

Vivani Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001753926-23-000298

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.